These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 31424008)

  • 1. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
    Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
    Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
    Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
    Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies for OXA-48-like and NDM producing
    Isler B; Aslan AT; Akova M; Harris P; Paterson DL
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1389-1400. PubMed ID: 36150216
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimum inhibitory concentrations of aztreonam-avibactam, ceftazidime-avibactam and meropenem in clinical isolates of Klebsiella pneumoniae harboring carbapenemase genes.
    Ageevets V; Sulian O; Avdeeva A; Chulkova P; Ageevets I; Gostev V; Alieva K; Golikova M; Sidorenko S
    J Antibiot (Tokyo); 2024 Oct; 77(10):706-710. PubMed ID: 38951709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical carbapenem-resistant
    Shahid M; Ahmad N; Saeed NK; Shadab M; Joji RM; Al-Mahmeed A; Bindayna KM; Tabbara KS; Dar FK
    Front Cell Infect Microbiol; 2022; 12():1033305. PubMed ID: 36304935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?
    Bocanegra-Ibarias P; Camacho-Ortiz A; Garza-González E; Flores-Treviño S; Kim H; Perez-Alba E
    J Glob Antimicrob Resist; 2020 Dec; 23():417-419. PubMed ID: 33212285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.
    Cabello M; Hernández-García M; Maruri-Aransolo A; Michelena M; Pérez-Viso B; Ponce-Alonso M; Cantón R; Ruiz-Garbajosa P
    J Glob Antimicrob Resist; 2024 Sep; 38():281-291. PubMed ID: 38996870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenem-resistant hypermucoviscous
    Wang Q; Chen M; Ou Q; Zheng L; Chen X; Mao G; Fang J; Jin D; Tang X
    Front Cell Infect Microbiol; 2022; 12():1083009. PubMed ID: 36619764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
    Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of ceftazidime-avibactam resistance in bla
    Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
    Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
    Öztaş S; Er DK; Dündar D; Keçeli SA
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):110-120. PubMed ID: 38837219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.